secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0001493152-22-018455
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo's ANEB-001 meets primary endpoint in Phase 2 ACI trial (p<0.0001)
-------------------------------------------------------------------------

- Primary endpoint VAS 'Feeling High' met (p<0.0001) for both 50mg and 100mg ANEB-001 vs placebo.
- Only 10% (50mg) and 30% (100mg) reported feeling high vs 75% placebo (p<0.001).
- ANEB-001 well tolerated; all AEs mild/transient except one moderate nausea/vomiting in 50mg group.
- Part B of study planned for Q3 2022; U.S. IND submission expected by end of 2022.
- Conference call at 8:30am ET today to discuss topline results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222018455/0001493152-22-018455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222018455/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-018455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer